Addressing Children’s Needs
Children are one of the most vulnerable yet neglected population in terms of access to HIV, TB and hepatitis C treatments. Paediatric treatments remain limited and sub-optimal. MPP and partners are accelerating the development and uptake of child-friendly formulations.
Long-acting therapeutics are emerging as gamechangers in healthcare by offering a simpler yet effective way of administering medicines that frees patients from daily pills, helps them stay on treatment & reduces burden on health systems. MPP is working on an access plan to ensure that as these products get developed, they are available to everyone, everywhere and at the same time.